Cortical function in asymptomatic carriers and patients with C9Orf72 amyotrophic lateral sclerosis

JAMA Neurology

Volumn 72, Issue 11, 2015, Pages 1268-1274

  Geevasinga, Nimeshan ^a   Menon, Parvathi ^a   Nicholson, Garth A ^b   Ng, Karl ^c   Howells, James ^d   Kril, Jillian J ^e   Yiannikas, Con ^c   Kiernan, Matthew C ^d   Vucic, Steve ^a  

^a University of Sydney   (Australia)

^b ANZAC RESEARCH INSTITUTE   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BRAIN CORTEX; BRAIN FUNCTION; C9ORF72 GENE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; EVOKED MUSCLE RESPONSE; FEMALE; FUNCTIONAL ASSESSMENT; GENE; GENE IDENTIFICATION; HETEROZYGOTE; HUMAN; LATENT PERIOD; LONGITUDINAL STUDY; MALE; MEMBRANE STEADY POTENTIAL; NERVE EXCITABILITY; NEUROPHYSIOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRANSCRANIAL MAGNETIC STIMULATION; VERY ELDERLY; FOLLOW UP; GENETICS; MIDDLE AGED; MOTOR EVOKED POTENTIAL; NERVE CELL INHIBITION; PHYSIOLOGY;

C9ORF72 PROTEIN, HUMAN; PROTEIN; REPETITIVE DNA;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; CASE-CONTROL STUDIES; CEREBRAL CORTEX; DNA REPEAT EXPANSION; EVOKED POTENTIALS, MOTOR; FEMALE; FOLLOW-UP STUDIES; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; NEURAL INHIBITION; PROTEINS; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84946751730     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.1872     Document Type: Article

References (36)

1. De Jesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245-256.
2. Renton AE, Majounie E, Waite A, et al; ITALSGEN Consortium. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257-268.
3. Majounie E, Renton AE, Mok K, et al; Chromosome 9-ALS/FTD Consortium; French research network on FTLD/FTLD/ALS; ITALSGEN Consortium. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11(4):323-330.
4. Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology. 2003;60(7):1094-1097.
5. Ciura S, Lattante S, Le Ber I, et al. Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann Neurol. 2013;74(2):180-187.
6. Mori K, Lammich S, Mackenzie IR, et al. hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations. Acta Neuropathol. 2013;125(3):413-423.
7. Donnelly CJ, Zhang P-W, Pham JT, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80(2):415-428.
8. Ling S-C, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79(3):416-438.
9. Ash PE, Bieniek KF, Gendron TF, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77(4):639-646.
10. Wainger BJ, Kiskinis E, Mellin C, et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 2014;7(1):1-11.
11. Vucic S, Ziemann U, Eisen A, Hallett M, Kiernan MC. Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. J Neurol Neurosurg Psychiatry. 2013;84(10):1161-1170.
12. Vucic S, Kiernan MC. Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain. 2006;129(pt 9):2436-2446.
13. Vucic S, Nicholson GA, Kiernan MC. Cortical hyperexcitabilitymay precede the onset of familial amyotrophic lateral sclerosis. Brain. 2008;131(pt 6):1540-1550.
14. Vucic S, Kiernan MC. Cortical excitability testing distinguishes Kennedy's disease from amyotrophic lateral sclerosis. Clin Neurophysiol. 2008;119(5):1088-1096.
15. Vucic S, Cheah BC, Yiannikas C, Kiernan MC. Cortical excitability distinguishes ALS frommimic disorders. Clin Neurophysiol. 2011;122(9):1860-1866.
16. de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119(3):497-503.
17. Cedarbaum JM, Stambler N, Malta E, et al; BDNF ALS Study Group (Phase III). The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169(1-2):13-21.
18. Turner MR, Cagnin A, Turkheimer FE, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C] (R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004;15(3):601-609.
19. Vucic S, Howells J, Trevillion L, Kiernan MC. Assessment of cortical excitability using threshold tracking techniques. Muscle Nerve. 2006;33(4):477-486.
20. de Carvalho M, Swash M. Nerve conduction studies in amyotrophic lateral sclerosis. Muscle Nerve. 2000;23(3):344-352.
21. Vucic S, Rothstein JD, Kiernan MC. Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends Neurosci. 2014;37(8):433-442.
22. Turner MR, Hardiman O, Benatar M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013;12(3):310-322.
23. Al-Sarraj S, King A, Troakes C, et al. p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. Acta Neuropathol. 2011;122(6):691-702.
24. Hanajima R, Ugawa Y, Terao Y, et al. Paired-pulse magnetic stimulation of the human motor cortex: differences among I waves. J Physiol. 1998;509(pt 2):607-618.
25. Vucic S, Lin CS-Y, Cheah BC, et al. Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain. 2013;136(pt 5):1361-1370.
26. Nihei K, McKee AC, Kowall NW. Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis patients. Acta Neuropathol. 1993;86(1):55-64.
27. Turner MR, Kiernan MC. Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis? Amyotroph Lateral Scler. 2012;13(3):245-250.
28. Blair IP, Williams KL, Warraich ST, et al. FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry. 2010;81(6):639-645.
29. Al-Chalabi A, Calvo A, Chio A, et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014;13(11):1108-1113.
30. Eisen A, Kiernan M, Mitsumoto H, Swash M. Amyotrophic lateral sclerosis: a long preclinical period? J Neurol Neurosurg Psychiatry. 2014;85(11):1232-1238.
31. Ramesh TM, Shaw PJ, McDearmid J. A zebrafish model exemplifies the long preclinical period of motor neuron disease. J Neurol Neurosurg Psychiatry. 2014;85(11):1288-1289.
32. Saba L, Viscomi MT, Caioli S, et al. Altered functionality, morphology, and vesicular glutamate transporter expression of cortical motor neurons from a presymptomatic mouse model of amyotrophic lateral sclerosis. Cereb Cortex. 2015; bhu317.
33. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V; Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996;347(9013):1425-1431.
34. Bensimon G, Lacomblez L, Meininger V; ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330(9):585-591.
35. Haidet-Phillips AM, Hester ME, Miranda CJ, et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol. 2011;29(9):824-828.
36. Vucic S, Cheah BC, Yiannikas C, Vincent A, Kiernan MC. Corticomotoneuronal function and hyperexcitability in acquired neuromyotonia. Brain. 2010;133(9):2727-2733.